SCHEMBL13623203

SCHEMBL13623203

CC(C)(C)OC(=O)Nc1cccc(NC(=O)CCc2cccc(Nc3nc(Cl)ncc3Cl)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 6/20 0.48
SYK P43405 1/20 0.47
STK17B O94768 1/20 0.45
STK17A Q9UEE5 1/20 0.45
ALK Q9UM73 5/20 0.44
SIRT2 Q8IXJ6 1/20 0.44
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
BRD4 O60885 1/20 0.42
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
CDK8 P49336 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
BTK Q06187 2/20 0.41
JAK3 P52333 1/20 0.41
EGFR P00533 1/20 0.40
RAF1 P04049 1/20 0.40
KDR P35968 1/20 0.40
MAP2K2 P36507 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13623023 0.91 MET (0.49) METSYKSTK17BSTK17AALK
SCHEMBL4180112 0.89 SYK (0.57) METSYKSTK17BSTK17AALK
SCHEMBL1025373 0.88 STK17B (0.52) METSYKSTK17BSTK17ASIRT2
SCHEMBL13623118 0.87 AURKA (0.50) METSYKSTK17BSTK17ABRD4
SCHEMBL13623131 0.87 SYK (0.50) METSYKSTK17BSTK17ASIRT2
SCHEMBL13623126 0.87 SYK (0.45) METSYKSTK17BSTK17AALK
SCHEMBL13623155 0.87 SYK (0.45) METSYKSTK17BSTK17ASIRT2
SCHEMBL13623059 0.86 STK17B (0.46) METSYKSTK17BSTK17ASIRT2
SCHEMBL13623129 0.86 SYK (0.47) METSYKSTK17BSTK17ASIRT2
SCHEMBL13623027 0.86 SYK (0.44) METSYKSTK17BSTK17ASIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK MET 599/4885SYK 46/4885STK17B 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.